Pulmonary Hypertension in Infants, Children, and Young Adults

Area of Science:

• Pediatric Cardiology
• Pulmonology
• Vascular Biology

Background:

• Pediatric pulmonary hypertension (PH) is a serious condition linked to cardiac, pulmonary, and systemic diseases, causing significant morbidity and mortality.
• Pulmonary hypertensive vascular disease (PHVD) involves inflammation, vascular remodeling, and angio-obliteration, leading to elevated pulmonary artery pressure, right ventricular dysfunction, and heart failure.

Purpose of the Study:

• To provide an update on recent developments in the diagnosis and treatment of PH in children and young adults.
• To focus on the heterogeneous etiology and pathophysiology of PH in the young, especially PHVD associated with congenital heart disease.
• To discuss new pharmacological, surgical, and interventional therapies for progressive/severe pulmonary arterial hypertension.

Main Methods:

• Review of recent advancements in PH-targeted therapies.
• Analysis of interventional-surgical procedures for PH/PHVD.
• Discussion of novel pharmacological and therapeutic strategies.

Main Results:

• Recent therapeutic and interventional advancements have improved quality of life and survival rates in pediatric PH/PHVD patients.
• Understanding of PHVD pathophysiology in young individuals, particularly those with congenital heart disease, has advanced.
• New treatment modalities show promise for severe cases unresponsive to conventional therapy.

Conclusions:

• The diagnosis and management of pediatric PH have evolved significantly with new therapeutic options.
• Targeted therapies and advanced interventions offer improved outcomes for children and young adults with PH.
• Further research into novel treatments is crucial for progressive and severe pulmonary arterial hypertension in the pediatric population.